Ono Pharmaceutical Company, Ltd., Bristol-Myers Squibb Company, And Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo (Nivolumab) And Mogamulizumab In Advanced Solid Tumors

TOKYO & OSAKA, Japan & NEW YORK--(BUSINESS WIRE)--Ono Pharmaceutical Co.,Ltd. (Tokyo: 4528), Bristol-Myers Squibb Company (NYSE:BMY) and Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151,“Kyowa Hakko Kirin”) announced today the companies have entered into a clinical trial collaboration agreement to conduct a Phase 1 combination study with Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor, and mogamulizumab, an anti-CCR4 antibody. The study, which will be conducted in Japan, will focus on evaluating the safety, tolerability and anti-tumor activity of combining Opdivo and mogamulizumab as a potential treatment option for patients with advanced or metastatic solid tumors.

Help employers find you! Check out all the jobs and post your resume.